EUCTR2021-002014-14-CZ进行中（未招募）1 期
Antibody and cellular response 28 days after the first dose of COVID-19 vaccine (Moderna) and then 33 weeks after the second dose and 8-12 weeks after the third dose in clinically stable patients with functional kidney transplantation.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. age 20 = 75 years
- •2. the ability to understand the nature and course of the study and to agree in writing to the study by signing Informed Consent
- •3. Day 28 after dosing Moderna
- •4. with a functional kidney transplant
- •5. with stable function of the transplanted kidney (graft)
- •6. more than 3 months after kidney transplantation
- •7. no change in immunosuppressive therapy and / or no infection since the Moderna dose was given
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •1. insufficient venous system in the upper limbs with the risk of having repeated intravenous injections to obtain a blood sample
- •2. past COVID-19 disease
- •3. concurrent participation in another clinical trial
- •4. pregnancy, breastfeeding
研究者
相似试验
进行中（未招募）
1 期
Evaluation of immunological response following a revaccination with a non-conjugated pneumococcal vaccine boosted or not by a conjugated pneumococcal vaccine in splenectomised patients (SPLENEVAC-2)Asplenic patients at risk for invasive pneumococcal diseasesMedDRA version: 20.0Level: PTClassification code 10041642Term: SplenectomySystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2018-003068-29-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)56
进行中（未招募）
1 期
Development of cellular immune response after infant pneumococcal conjugate vaccinations - Pneumococcal cellular immune responseCellular immune response(long term memory) after following the infant immunisation programme with a pneumococcal conjugate vaccine (Prevenar).EUCTR2008-004489-23-NLetherlands Vaccine Institute100
已完成
4 期
Development of cellular immune response after infant pneumococcal conjugate vaccinationsImmunogenicitymemory10004018NL-OMON32887ederlands Vaccin Instituut100
进行中（未招募）
1 期
Immunity after Tick Borne Encephalitis vaccination in stem cell transplanted patientsPatients have undergone allogeneic or autologous stem cell transplantation for hematological malignancies.EUCTR2014-003573-42-SEVästra Götalandsregionen90
招募中
不适用
CIMAvax-EGF in different maintenance schemeson small cell lung cancerCarcinoma, Non-Small-Cell LungCarcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsLung DiseasesRespiratory Tract DiseasesNSCLCRPCEC00000368Center of Molecular Immunology (CIM)42